South Africa Pulmonary Arterial Hypertension Market Size & Outlook
South Africa pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
South Africa pulmonary arterial hypertension market highlights
- The South Africa pulmonary arterial hypertension market generated a revenue of USD 181.2 million in 2023 and is expected to reach USD 275.1 million by 2030.
- The South Africa market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 181.2 million |
| Market revenue in 2030 | USD 275.1 million |
| Growth rate | 6.2% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, South Africa accounted for 2.5% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 53.1 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.3% in 2023. Horizon Databook has segmented the South Africa pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Governments and healthcare organizations are undertaking initiatives to improve the healthcare facilities in the respective MEA countries. South Africa PAH market stood at USD 42.6 million in 2015. Economic development of South Africa and the presence of high unmet healthcare needs are some primary growth drivers of this market.
High burden of associated diseases such as HIV which vital factor for development of PAH. Expected growth in healthcare spending and the resultant rising demand for advanced healthcare treatments is anticipated to boost the market during the forecast period. Moreover, the government of the country is directing efforts toward regulating the healthcare industry in South Africa.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
South Africa Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
